Fifteen-year survival in prostate cancer: A prospective, population- based study in Sweden

JAMA

Volumn 277, Issue 6, 1997, Pages 467-471

  Johansson, Jan Erik ^a,b   Holmberg, Lars ^b   Johansson, Sara ^a   Bergström, Reinhold ^b,c   Adami, Hans Olov ^b,d  

^a ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d HARVARD CENTER FOR CANCER PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRAMUSTINE; ESTROGEN; FLUTAMIDE; MEDROXYPROGESTERONE ACETATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER;

EID: 0031028711     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.6.467     Document Type: Article

References (46)

1. Catalona WJ, Smith DS, Ratliff TL, Baslar JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
2. Littrup PJ, Goodman AC, Mettlin CJ. The benefit and cost of prostate cancer early detection. CA Cancer J Clin. 1993;43:134-149.
3. Chodak GW. Questioning the value of screening for prostate cancer in asymptomatic men. Urology. 1993;42:116-118.
4. Fracchia JA. Costs and other aspects of screening vs early detection of prostate cancer. Prim Care Cancer. 1993;13:31-32.
5. Waterbor JW, Beuschen AJ. Prostate cancer screening (United States). Cancer Causes Control. 1995;6:267-274.
6. Johansson J-E, Adami H-O, Andersson S-O, Bergström R, Krusemo UB, Kraaz W. Natural history of localized prostate cancer: a population based study in 223 untreated patients. Lancet. 1989;1:799-803.
7. Johansson J-E, Adami H-O, Andersson S-O, Bergström R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992;267:2191-2196.
8. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330:242-248.
9. Scardino PT. Early detection of prostate cancer. Urol Clin North Am. 1989;16:635-655.
10. Aus G, Hugosson J, Norlén L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol. 1995;154:460-465.
11. Chodak G. What to expect from prostate cancer. J Urol. 1995;154:2132-2133.
12. Nitti V, Lepor H. Controversies old and new. Lancet. 1995;346(suppl 26).
13. Otnes B, Harvei S, Fosså SD. The burden of prostate cancer from diagnosis until death. Br J Urol. 1995;76:587-594.
14. Abrahamsson PA, Adami H-O, Kim KM, Zelen M, Kulldorf M. Re: long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol. 1996; 155:296-298.
15. Grönberg H. Prostate Cancer: Epidemiological Studies. Umeå, Sweden: Ume̊ University; 1995. Medical dissertation No. 431.
16. Franzén S, Giertz G, Zaijcek J. Cytological diagnosis of prostatic tumours by transrectal aspiration biopsy: a preliminary report. J Urol. 1960; 32:193-196.
17. International Union Against Cancer. TNM Classification of Malignant Tumours. Rev 3rd ed. Geneva, Switzerland: International Union Against Cancer; 1978.
18. World Health Organization. International Histological Classification of Tumours: Histological Typing of Prostate Tumours. Geneva, Switzerland: World Health Organization; 1980; No. 22.
19. Johansson J-E, Andersson S-O, Holmberg L, Bergström R. Primary orchiectomy versus estrogen therapy in advanced prostatic cancer: a randomized study: results after 7 to 10 years of follow-up. J Urol. 1991;145:519-523.
20. Johansson J-E, Andersson S-O, Beckman KW, Lingårdh G, Zador G. Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate. Urology. 1987; 29:55-59.
21. Johansson J-E, Andersson S-O, Holmberg L. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. Br J Urol. 1991;68:67-73.
22. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis. 1958;8:699-710.
23. Ederer F, Axtell IM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101-121.
24. Hakulinen T. On long-term relative survival rates. J Chronic Dis. 1977;30:431-443.
25. Cox DR. Regression model and life tables. J R Stat Soc. 1972;B34:187-220.
26. Stenbäck M, Rosén M. Cancer survival in Sweden in 1961-1991. Acta Oncol. 1995;34(suppl 4):62-63.
27. Cancer Registry of Norway. Survival of Cancer Patients: Cases Diagnosed in Norway 1968-1975. Oslo: The Norwegian Cancer Registry; 1980.
28. Hakulinen T, Pukkala E, Hakama M, et al. Survival of cancer patients in Finland in 1953-1974. Ann Clin Res. 1981;13(suppl 31):59-61.
29. Tretli S, Engeland A, Haldorsen T, et al. Prostate cancer: look to Denmark. J Natl Cancer Inst. 1996;88:128.
30. Levi F, Randimbison L, Te V-C, et al. Trends in cancer survival in Vaud, Switzerland. Eur J Cancer. 1992;28A:1490-1495.
31. Helgesen F, Holmberg L, Johansson J-E, Bergström R, Adami H-O. Trends in prostate cancer survival in Sweden 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst. 1996;88:1216-1221.
32. Wingo PA, Tong T, Bolden S. Cancer statistics. CA Cancer J Clin. 1995;45:8-30.
33. Graversen PH, Corle DK, Nielsen KT, Madsen PO, Casser TC. Radical prostatectomy versus expectant primary treatment in stage I and II prostate cancer: a fifteen-year follow-up. Urology. 1990; 36:493-498.
34. Iversen P, Madsen ÅP, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate: twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol. 1995;172(suppl):65-72.
35. Adolfsson J, Steineck G, Whitmore WF Jr. Recent results of management of palpable clinically localized prostate cancer. Cancer. 1993;72:310-322.
36. Austenfeld MS, Thompson IM Jr, Middleton RG, for the American Urological Association Prostate Cancer Guideline Panel. Meta-analysis of the literature: guideline development for prostate cancer treatment. J Urol. 1994;152:1866-1869.
37. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG Jr, Wennberg JE, for the Prostate Disease Patient Outcome Research Team. A structured literature review of treatment for localized prostate cancer. Arch Fam Med. 1993;2: 487-493.
38. Albertsen P, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274:626-631.
39. Chodak GW, Bibbi M, Straus FH, Wed GL. Transrectal aspiration biopsy versus transperineal core biopsy for the diagnosis of carcinoma of the prostate. J Urol. 1984;132:480-482.
40. Waisman J, Adolfsson J, Löwhagen T, Skoog L. Comparison of transrectal prostate digital aspiration and ultrasound-guided core biopsies in 99 men. Urology. 1991;37:301-307.
41. 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994;344:1594-1598.
42. Pearson JD, Carter HB. Natural history of changes in prostate specific antigen in early-stage prostate cancer. J Urol. 1994;152:1743-1748.
43. Tibblin G, Welin L, Bergström R, Ronquist G, Norlén B-J, Adami H-O. The value of prostate specific antigen in early diagnosis of prostate cancer: the study of men born in 1913. J Urol. 1995;154: 1386-1389.
44. Schröder FH. Detection of prostate cancer. BMJ. 1995;310:140-141.
45. Adami H-O, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet. 1994;343: 958-960.
46. Johansson J-E, Abrahamsson PA, Adami H-O, et al. Massundersökning för prostatacancer [Mass screening for prostate cancer]. Stockholm: Swedish Council on Technology Assessment in Health Care; 1995. Report No. 126.